London - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Ephedrine Sulfate Injection, USP, 50mg/mL, in the US, through its US affiliate, Hikma Pharmaceuticals USA Inc.

Ephedrine Sulfate Injection, USP is an alpha- and beta- adrenergic agonist and a norepinephrine releasing agent indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia.

According to IQVIA, US sales of Ephedrine Sulfate Injection, USP, 50mg/mL, were approximately $64 million in the 12 months ending November 2020.

Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Contact:

David Belian

Tel: +1 732 720 2830

(C) 2021 Electronic News Publishing, source ENP Newswire